| INTRODUCTION
The most common risk factors of chronic kidney disease are diabetes and hypertension. 1 Preventing chronic kidney disease and early diagnosis of kidney damage are an important goal in primary health
care. According to the Korea Health Insurance Review and Assessment
Service, the number of Korean patients with chronic kidney disease increased by 37.1%, and total medical expenses increased by 47.6%, from 2006 to 2010. The average annual growth rate for the 5-year period is of about 8.2% and 10.2%, respectively. According to the 2012 data, the total expenses for medical treatment of patients with endstage renal failure is similar to those of all cancer patients, and the expenses of medical treatment per patient are the highest among all diseases. 2, 3 Therefore, in patients with a high potential risk of kidney function, it is essential to periodically monitor the kidney function and to treat the progressive slowing down of the renal function as early as possible. 1, [4] [5] [6] [7] [8] An increased excretion of urinary protein, especially albumin, is an early finding of renal damage, and measurement of urinary albumin has been a useful marker for diagnosis and follow-up of renal failure with estimated glomerular filtration rate. 4, 9 The urine albumin/ creatinine ratio (ACR) test is also used to screen patients with chronic diseases that put them at an increased risk of developing kidney disease. ACR is a surrogate marker of urine albuminuria. 6 A quantitative evaluation of moderately increased albuminuria requires the use of expensive biochemical instruments and reagents, making it difficult to perform in small or medium-sized clinics. Even if an evaluation has been performed, it needs to be sent to a central clinical laboratory, so it is difficult to conduct an early diagnosis and frequent monitoring.
As such, the availability of point-of-care testing (POCT) instruments is important. POCT tools are rapidly expanding, and the availability of quick results appears to improve patient outcomes.
10,11
Hence, evidence for POCT instruments of analytical quality is necessary to achieve good patient outcomes. In this study, we evaluated the performance of the URiSCAN 2 ACR Strip (URiSCAN; YD diagnostics, Yongin, Korea), a semiquantitative point-of-care testing (POCT) assay, and compared its results to those of an existing POCT assay and a quantitative assay.
| MATERIALS AND METHOD

| Specimens from patients
We analyzed random, midstream urine specimens among those re- 
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All tests were completed within two hours after urine collection, and a total of 1020 specimens were selected by applying the following exclusion criteria: 
| Assays
| Quantitative assay
Urine albumin and creatinine were measured with the quantitative Tina-quant Albumin Gen.2 and COBAS INTEGRA Creatinine Jaffe
Gen.2 (Roche Diagnostics, Basel, Switzerland) using a quantitative analyzer, Cobas Integra 800. Urine albumin was measured using an immunoturbidimetric principle and its analytical range was 3.0-210.0 mg/L. Urine creatinine was quantitated using the Jaffe-kinetic method, and its analytical range was 0.31-367 mg/dL. Specimens showing concentrations above the analytical measurement limit were repeatedly measured after 1:10 dilution with normal saline.
| Semiquantitative assays
Urine albumin and creatinine were measured via the colorimetric method using sulfonephthalein dye-binding and creatinine-metal CLINITEK classifies the results of albumin, creatinine, and ACR using the same categories as those of URiSCAN. The normal value of ACR was defined as <30 mg/g, 13 and abnormal values were defined as 30-300 mg/g and >300 mg/g in both strips.
| Precision of the URiSCAN 2 ACR Strip
To evaluate the precision, albumin and creatinine solutions of three concentrations (cutoff, C 50 ; C 50-−20%; C 50 +20%) using quality control materials (Bio-rad, Irvine, USA) were prepared. Each concentration was repeatedly measured 40 times using URiSCAN according to the Clinical and Laboratory Standards Institute (CLSI) EP12-A2; User
Protocol for Evaluation of Qualitative Test Performance; Approved
Guideline. To verify the good precision of a qualitative reagent, we
should prove that C 5 -C 95 interval should be included within the concentration range between C 50 −20% and C 50 +20% and concentrations 20% or more away from C 50 should yield consistent results. C 5 is the concentration at which 5% of the tests showed positive and 95%
showed negative results when many replicates of a single sample at the concentration are tested. C 95 is the concentration at which 95% of tests showed positive and 5% showed negative results.
| Concordance among assays
Quantitative albumin concentration measurements of <20, ≥20-<56, ≥56-<116, and ≥116 mg/L were assigned categories defined by negative, 1+, 2+, and 3+ according to semiquantitative assay grades, respectively. Quantitative creatinine concentration measurements of <30, ≥30-<81, ≥81-<181, ≥181-<281, and ≥281 mg/dL were matched to categories defined by negative, 1+, 2+, 3+, and 4+, according to semiquantitative assay grades, respectively. Quantitative ACR results of <30, 30-300, and >300 mg/g were regarded as normal, moderately increased albuminuria, and proteinuria, respectively. We compared the grades of albumin, creatinine, and ACR results of the URiSCAN to those of CLINITEK. The concordance rate between the quantitative and each semiquantitative method was also evaluated after converting the quantitative results to semiquantitative grades.
| Statistical analysis
Sensitivity, specificity, positive predictability, negative predictability, and likelihood ratios with 95% confidence interval were calculated for each semiquantitative method based on the quantitative assay results. STATA version 14.0 (StataCorp LP, College Station, TX, USA)
was used for the calculation.
| RESULTS
| Precision of the URiSCAN 2 ACR Strip
The and C 50 +20% bounded the C 5 -C 95 interval with 85.8% confidence.
| Comparison of the quantitative and semiquantitative method
The distribution of albumin concentrations of 1,020 random urine specimens were measured using a quantitative assay as follows: 
| Comparison of the ACR results between the URiSCAN 2 ACR Strip and the CLINITEK microalbumin 2 Strip
The overall concordance rate of the ACR results between the two semiquantitative POCT assays was 75.3% (95%CI: 72.5%-77.9%). Bold characters: number of concordant results. Abbreviations: ACR, albumin-to-creatinine ratio; CI, confidence interval.
40 specimens (3.92% of total specimens). In addition, six specimens showed results of an ACR greater than 300 mg/g with CLINITEK and less than 30 mg/g with URiSCAN. These specimens showed quantitative ACR concentrations between 75.42 and 204.37 (median; 112.17) mg/g, which were also false-negative results for URiSCAN (Table 3) . 30-300 mg/g 105 304 42
>300 mg/g 2 37 105
Bold characters: number of concordant results. ACR, albumin-to-creatinine ratio; CI, confidence interval.
| DISCUSSION
Moderately increased albuminuria is considered as a screening marker for kidney damage, and it is used as the first clinical indicator for diabetic kidney disease. [14] [15] [16] The 2015 American Diabetes Association (ADA) guideline recommends at least an annual albuminuria screen with a random spot urine sample for urine ACR in patients with 5 years of diabetes, 17 and a POCT that can obtain ACR results within a few minutes is also available. In this study, the overall concordance rate between the URiSCAN and the quantitative assay on ACR was 75.6%, and that for ACR ≥1+ (≥30 mg/g) grades was 78.8%, and these results were much improved since the first evaluation totaling 219 urine specimens. In the first evaluation, the overall concordance rate was 74.0%, and that for ACR ≥ 1+ grades was 45.9%. In addition, the analytical sensitivity also improved (87.7% vs 45.9%), but the specificity decreased (72.2% vs 84.8%). 18 Although the above changes might be partially a result of a higher positive rate of albuminuria (70.6% vs 27.9%), the improvement in the strips may result in a dramatic increase in the sensitivity. URiSCAN changed the formulation to decrease the lotto-lot variation and reduce the effect of urine buffering capacity and urine pH. This improvement allows a reduction in the false-negative results and an improvement in the sensitivity over the previous strip version, while the frequency of false-positives increased due to a low specificity. Semiquantitative ACR assays, including URiSCAN used in this study, measure moderately increased albuminuria or severely increased albuminuria with earlier and user-friendly convenience than sending to the main laboratory. In summary, URiSCAN showed a comparable sensitivity and lower specificity than CLINITEK. Since URiSCAN showed a relatively low positive predictive value and a high negative predictive value, the frequency of false-positive results was high. Therefore, URiSCAN would be appropriate as a screening test to exclude albuminuria, but additional tests will be necessary to confirm albuminuria. Also, it is thus necessary to improve the test strips to decrease the false-positive results by improving the specificity for albumin.
